Stoke Therapeutics grants options and RSUs to officer

Stoke Therapeutics reported that Chief Patient Officer Jason Hoitt received new equity awards.

Rhea-AI Filing Summary

Stoke Therapeutics reported that Chief Patient Officer Jason Hoitt received new equity awards. He was granted employee stock options covering 72,000 shares at an exercise price of $0.0000 per share and 48,000 restricted stock units, each representing one share of common stock.

The option award vests monthly over four years, beginning with 1/48 of the total on March 15, 2026. The RSU award vests in four equal annual installments, with the first quarter vesting on February 15, 2027, in each case subject to his continued service.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 2 txns

Insider Hoitt Jason

Role Chief Patient Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	72,000	$0.00	$0.00
Grant/Award	Restricted Stock Units	48,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 72,000 contracts (Direct); Restricted Stock Units — 48,000 contracts (Direct)

Footnotes (3)

1. F1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
3. F3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Jason Hoitt receive from Stoke Therapeutics (STOK)?

Jason Hoitt received stock options on 72,000 shares and 48,000 restricted stock units. The options give him the right to buy common stock, while each RSU converts into one share upon vesting and settlement, subject to continued service conditions.

How do the new stock options for Jason Hoitt at Stoke Therapeutics (STOK) vest?

The 72,000-share option grant vests in 48 equal monthly installments. Vesting begins with 1/48 of the total on March 15, 2026, with an additional 1/48 vesting on each monthly anniversary, contingent on Jason Hoitt’s continued service to the company.

What is the vesting schedule for Jason Hoitt’s RSUs at Stoke Therapeutics (STOK)?

Jason Hoitt’s 48,000 restricted stock units vest in four equal annual tranches. The first 1/4 of the award vests on February 15, 2027, with remaining annual tranches also requiring his continued service through each respective vesting date.

What does each RSU granted to Jason Hoitt by Stoke Therapeutics (STOK) represent?

Each restricted stock unit represents a contingent right to receive one share of Stoke Therapeutics common stock. Shares are delivered upon settlement after vesting, assuming all service-based conditions are met, effectively functioning as deferred stock-based compensation for the executive.

Are Jason Hoitt’s new equity awards at Stoke Therapeutics (STOK) dependent on continued employment?

Yes, both the stock options and RSUs require continued service. The options vest monthly starting March 15, 2026, and the RSUs vest annually starting February 15, 2027, with each vesting installment conditioned on Jason Hoitt remaining with Stoke Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoitt Jason

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Patient Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.09	02/17/2026		A		72,000		(1)	02/16/2036	Common Stock	72,000	$0	72,000	D
Restricted Stock Units	(2)	02/17/2026		A		48,000		(3)	02/15/2030	Common Stock	48,000	$0	48,000	D

Explanation of Responses:

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.